CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

125274Orig1s000

MICROBIOLOGY REVIEW(S)
Date: December 11, 2008
To: Administrative File, STN 125274
From: Donald Obenhuber, Ph.D., CDER/OC/DMPQ/MAPCB/BMT
Endorsement: Patricia F. Hughes, Ph.D., Team Leader, CDER/OC/DMPQ/BMT
Edwin Rivera, Branch Chief, CDER/OC/DMPQ/MAPCB
Subject: Review of BLA for the treatment of cervical dystonia (spasmodic torticollis)
US License: 1787
Applicant: Ipsen Biopharm Limited
Facility: Ipsen Biopharm, Limited Wrexham LL13 9UF, UK, FEI=1000346340
Product: Dysport® for Injection (Clostridium Botulinum Toxin Type A Hemagglutinin Complex)
Dosage: 300 U/vial or 500 U/vial (sterile lyophilized power); in single use 3ml stoppered glass vials with flip top seals is to be reconstituted with 1 mL of 0.9% Sodium Chloride Injection USP (without preservative) intended for intramuscular injection.
Indication: Treatment of cervical dystonia (spasmodic torticollis)
Due date: 28 December 2008

RECOMMENDATION ON APPROVABILITY: The submission, as amended, is recommended for approval on the basis of sterility assurance. All deficiencies identified (deficiencies are listed on page 27-29 of this review) during the assessment of this BLA were adequately addressed by the sponsor and the BLA was appropriately amended.

The following amendments were submitted in response to microbiology product quality deficiencies identified during the review of the BLA.

Amendment 18, September 18, 2008
Amendment 19, September 19, 2008
Amendment 27, December 3, 2008
Amendment 28, December 9, 2008

PRODUCT QUALITY MICROBIOLOGY ASSESSMENT

MANUFACTURING PROCESS
CNT52120 Bulk Active Substance (BAS) Clostridium botulinum toxin Type A haemagglutinin complex is manufactured using the following chemical components (3.2.P.1):

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Vial Content</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>300 U/vial</td>
<td>500 U/vial</td>
</tr>
<tr>
<td>CNT52120</td>
<td>(Lyophilized)</td>
<td>(b) (4)</td>
</tr>
<tr>
<td>Albumin Human</td>
<td>125 µg</td>
<td></td>
</tr>
<tr>
<td>Lactose monohydrate</td>
<td>2.5 mg</td>
<td></td>
</tr>
</tbody>
</table>

The following represents the components comprising the container/closure systems. Drug Product is supplied in Type I neutral 3 mL glass vials, sealed with 13 mm rubber closures and oversealed with 13 mm flip top seals. The color of the flip off top on the seal is unique to the CNT52120 Drug Product concentration.

<table>
<thead>
<tr>
<th>Container Closure Component</th>
<th>Manufacturer/Supplier/Address</th>
<th>Description of the Component</th>
<th>Material of Construction Pharmacopoeia Compliance</th>
<th>DMF No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glass vial</td>
<td></td>
<td></td>
<td></td>
<td>(b) (4)</td>
</tr>
<tr>
<td>Closure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flip top overseal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The following summarizes the batch composition

26 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page
Container Closure Integrity

Please provide stability data for Container Closure Integrity testing.